<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: p38-Alpha <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase (p38-MAPK) is a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor often mutated in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, but its specific role in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is not completely understood </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies have found that p38-MAPK activity inhibits epithelial proliferation and promotes <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in the intestine </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we sought to test the hypothesis that intestinal disruption of p38-MAPK would lead to increased <z:mp ids='MP_0002006'>tumorigenesis</z:mp> in the colon </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: p38-MAPK was deleted in mice within the intestinal epithelium using a <z:chebi fb="3" ids="41774">tamoxifen</z:chebi>-inducible Cre system under control of the villin promoter [villin-Cre ERT2(+), MAPK14(f/f)] </plain></SENT>
<SENT sid="4" pm="."><plain>An azoxymethane and <z:chebi fb="0" ids="52071">dextran</z:chebi> <z:chebi fb="0" ids="32149">sodium sulfate</z:chebi> protocol was used to drive <z:e sem="disease" ids="C0021841" disease_type="Neoplastic Process" abbrv="">intestinal tumor</z:e> development </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> measurements were made using computer software from photographs of excised colon specimens </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The number of mice that developed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> was not statistically different when comparing <z:mp ids='MP_0002169'>wild-type</z:mp> mice (7/14) to inducible, intestine epithelial-deleted p38-MAPK (9/11) mice after azoxymethane/<z:chebi fb="0" ids="52071">dextran</z:chebi> <z:chebi fb="0" ids="32149">sodium sulfate</z:chebi> treatment (P = .21) </plain></SENT>
<SENT sid="7" pm="."><plain>However, the epithelial-deleted p38-MAPK mice developed significantly more <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (3.7 vs 1.1; P = .008) and nearly 4 times the total <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden as <z:mp ids='MP_0002169'>wild-type</z:mp> mice (17.4 vs 4.8Â mm(2); P = .03) </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0002169'>Wild-type</z:mp> and epithelial-deleted p38-MAPK groups demonstrated a similar degree of colon <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Deletion of p38-MAPK within the colonic mucosa leads to a hyperplastic state promoting greater <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development </plain></SENT>
<SENT sid="10" pm="."><plain>Because the severity of <z:hpo ids='HP_0002583'>colitis</z:hpo> was not augmented in mice with p38-MAPK deficiency, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development is likely mediated by impaired cell cycle regulation within the colonic epithelium </plain></SENT>
<SENT sid="11" pm="."><plain>Manipulation of p38-MAPK activity may provide a novel treatment and/or prevention strategy in the management of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, particularly in the setting of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> </plain></SENT>
</text></document>